Our portfolio company, Immunitas Therapeutics, has announced a $478 Million global licensing agreement of their preclinical antibody program to advance treatments for chronic inflammatory diseases with Boehringer Ingelheim. The program is designed to selectively target cells that play a central role in driving chronic inflammation, with the goal of achieving sustained disease control for patients who do not respond adequately to current therapies.
“This program is the result of insights into human biology that Immunitas explored extensively preclinically. Partnering with Boehringer Ingelheim enables us to advance this novel therapeutic into clinical development with a global organization that has deep expertise in immunology and drug development,” said Amanda Wagner, President and Chief Executive Officer of Immunitas Therapeutics. “We believe this collaboration has the potential to translate our science into new treatment options for patients living with chronic inflammatory diseases who need better solutions.”
Chronic inflammatory and autoimmune diseases affect millions of people worldwide and can significantly impact quality of life. While current therapies have improved outcomes for some patients, many experience limited or diminishing benefit over time. New approaches that address the underlying drivers of inflammation are needed to achieve longer-lasting disease control.
Immunitas is a clinical stage precision immunotherapy company dedicated to discovering and developing novel treatments for patients with cancer and autoimmune disease. The company was founded in 2019 by Longwood Fund with leading scientists from Dana-Farber Cancer Institute, Massachusetts General Hospital, Broad Institute, and Massachusetts Institute of Technology. Immunitas is supported by a strong syndicate of investors including Agent Capital, Alexandria Venture Investments, Evotec, Leaps by Bayer, Longwood Fund, M Ventures, Medical Excellence Capital, and Novartis Venture Fund.
Read the full press release here.
